Table 2.
Formulation code | X1 phospholipid type | X2 SC conc. (%) | R1 EE (%) | R2 ZP (mV) | R3 PS (nm) | PDI |
---|---|---|---|---|---|---|
F1 | PDC | 0.1 | 96.98 ± 1.4 | −15.13 ± 2.03 | 168.17 ± 0.08 | 0.008 ± 0.023 |
F2 | PDC | 0.3 | 91.04 ± 2.6 | −21.20 ± 1.56 | 200.23 ± 1.05 | 0.005 ± 0.072 |
F3 | PDC | 0.6 | 87.33 ± 2.45 | −28.22 ± 1.14 | 265.2 ± 0.32 | 0.002 ± 0.112 |
F4 | PDS | 0.1 | 90.21 ± 1 | −27.05 ± 1.08 | 111.68 ± 1.4 | 0.006 ± 0.023 |
F5 | PDS | 0.3 | 86.11 ± 0.94 | −30.96 ± 1.12 | 141.99 ± 0.98 | 0.004 ± 0.091 |
F6 | PDS | 0.6 | 81.08 ± 1.7 | −35.11 ± 1.56 | 206.78 ± 1.2 | 0.003 ± 0.012 |
Cholesterol (CH) and pluronic 123 (P 123) were kept constant in all formulae at 0.3 and 0.6%, respectively.